PROJECT FACTSHEET



EU4Monitoring Drugs (EU4MD)

Period of implementation: 01.01.2019 - 31.12.2021

EaP countries:

Armenia, Azerbaijan, Belarus, Georgia, Republic of

Moldova, Ukraine

EU contribution: € 3 000 000

Implementing organisation(s):

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)

more e

If problem
drug is less
hered to be
extendess, the
y or essulting
bur of new cleenly
mrs, although stell
15 %, with around it
1. In some countries
coert increases in dru
tected alongside oppoi
urs of Europe where it is
deadon, the role played by
sandiosocular disease mit
available, they show an ow
emergency presentations, wil
emonly reported licits

and Scharolic Countries

and Development's

Social media account links:

Project website: emcdda.europa.eu/activities/eu4md_en

Project description:

The EU-supported "EU4Monitoring Drugs" project involves countries in the European Neighbourhood Policy (ENP) area. It supports national and regional readiness to identify and respond to drug-related security and health threats.

Expected results:

Networking and partnership are central to EU4MD. The project deploys a participatory approach to capacity-building ('learning by doing') and activities focus on developing practical and scientific knowledge, along with the skills of professionals and organisations.

On the supply side, EU4MD aims to support a better understanding of drug markets; capacity development for forensic analysis; assessment of the environmental impact of drug production; identification of 'hot spots'; mapping of production and trafficking dynamics; technological innovations; threat assessment and responses to emerging issues.

On the demand side, work is focused on identifying trends in prevalence and patterns of drug use; drug-related harms; supporting treatment, harm-reduction and prevention activities; dissemination of innovative monitoring approaches; development of gender-appropriate responses and assessment and promotion of services for vulnerable populations.

Proven tools and methods developed by the EMCDDA are put to use in order to improve drug monitoring and support the introduction of evidence-based practices to better respond to the health and social problems resulting from drug use and the drug market.

Factsheet generated: 19.05.2024